By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

KAI Pharmaceuticals, Inc. (Acquired by Amgen) 

270 Littlefield Road

South San Francisco  California  94080  U.S.A.
Phone: 650-244-1100 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Amgen (AMGN) Completes Acquisition of KAI Pharmaceuticals, Inc. 7/6/2012 9:23:25 AM
Amgen (AMGN) to Pay $315 Million for Privately-Held KAI Pharmaceuticals, Inc. 4/10/2012 7:47:19 AM
KAI Pharmaceuticals, Inc. Announces Initiation of Second Phase 2 Study of KAI-4169 1/6/2012 6:39:42 AM
KAI Pharmaceuticals, Inc. Announces Late Breaker Poster Presentation of KAI-4169 Phase 2 Clinical Results at the American Society of Nephrology’s Kidney Week 2011 11/11/2011 6:46:27 AM
KAI Pharmaceuticals, Inc. Inks $13 Million Development Deal with Ono Pharmaceutical Company, Ltd. 9/15/2011 6:44:31 AM
KAI Pharmaceuticals, Inc. Announces Promising Results of KAI-4169 Program for the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder 6/7/2011 8:40:42 AM
KAI Pharmaceuticals, Inc. Announces Advancement of KAI-4169 Clinical Program into a Phase 2 Trial 3/14/2011 10:03:31 AM
KAI Pharmaceuticals, Inc. Announces Initiation of Phase 1b Study of KAI-4169 for the Treatment of Secondary Hyperparathyroidism (SHPT) 9/27/2010 10:06:05 AM
KAI Pharmaceuticals, Inc. Announces Phase 1 Results of KAI-4169 for the Treatment of Secondary Hyperparathyroidism (SHPT) 7/20/2010 8:27:22 AM
Altea Therapeutics and KAI Pharmaceuticals, Inc. Enter into a Preclinical and Clinical Development Agreement for the Transdermal Delivery of Certain Novel KAI Peptides 1/13/2010 9:32:04 AM
1234
//-->